Loading...

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

Poly(ADP-ribose)polymerase inhibitors (PARPis) have shown promising activity in patients with BRCA1/2 mutation-associated (BRCA1/2(MUT+)) ovarian and breast cancers. Accumulating evidence suggests that PARPi may have a wider application in the treatment of sporadic high-grade serous ovarian cancer,...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Lee, J-m., Ledermann, J. A., Kohn, E. C.
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2014
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3868320/
https://ncbi.nlm.nih.gov/pubmed/24225019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt384
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!